Álcool (S)-(−)-perílico ≥95%, FG

Sinônimo(s):

p-Menta-1,8-dien-7-ol

Fórmula empírica (Notação de Hill):

C₁₀H₁₆O

Número CAS:

18457-55-1

Peso molecular:

152.23

Número FEMA:

2664

Conselho da Europa nº:

2024

Número MDL:

MFCD00062995

Código UNSPSC:

12164502

ID de substância PubChem:

24901225

Número de Flavis:

2.060

NACRES:

NA.21

fonte biológica

synthetic

Nível de qualidade

400

grau

FG
Halal
Kosher

conformidade reg.

EU Regulation 1334/2008 & 178/2002
FDA 21 CFR 117
FDA 21 CFR 172.515

Ensaio

≥95%

atividade óptica

[α]20/D −88°, c = 1 in methanol

índice de refração

n20/D 1.501 (lit.)

pb

119-121 °C/11 mmHg (lit.)

densidade

0.96 g/mL at 25 °C (lit.)

aplicação(ões)

flavors and fragrances

Documentação

see Safety & Documentation for available documents

alérgeno alimentar

no known allergens

Organoléptico

fatty; green

cadeia de caracteres SMILES

CC(=C)[C@H]1CCC(CO)=CC1

InChI

1S/C10H16O/c1-8(2)10-5-3-9(7-11)4-6-10/h3,10-11H,1,4-7H2,2H3/t10-/m1/s1

chave InChI

NDTYTMIUWGWIMO-SNVBAGLBSA-N

Aplicação

• CYP108N12 initiates p-cymene biodegradation in Rhodococcus globerulus.: This study explores the enzymatic breakdown pathways of monoterpenes, using (S)-(−)-Perillyl alcohol as a precursor, offering insights into microbial degradation processes that could be vital for bioremediation efforts or synthetic biology applications (Giang et al., 2022).

• Orofacial antinociceptive effects of perillyl alcohol associated with codeine and its possible modes of action.: Research demonstrates the pain-relieving properties of (S)-(−)-Perillyl alcohol when combined with codeine, highlighting its potential for developing new analgesic formulations in dental and facial pain management (Limeira et al., 2022).

• Orofacial antinociceptive activity of (S)-(-)-perillyl alcohol in mice: a randomized, controlled and triple-blind study.: This study underpins the effectiveness of (S)-(−)-Perillyl alcohol in reducing orofacial pain in a controlled experimental setup, providing a basis for further clinical trials in pain management (Tomaz-Morais et al., 2017).

• In Vivo Anti-Tumor Activity and Toxicological Evaluations of Perillaldehyde 8,9-Epoxide, a Derivative of Perillyl Alcohol.: Highlights the anti-tumor properties of a novel derivative of (S)-(−)-Perillyl alcohol, suggesting its potential as a therapeutic agent in oncology, with comprehensive studies on its efficacy and safety (Andrade et al., 2016).